Scl:Cdx2-induced MDS with secondary transformation to AML (sAML) is mediated by common oncogenic mutations seen in human disease, and thus, this model provides an opportunity to examine the preclinical efficacy of anti-leukemic drugs. Here, CDX2 is linked to acute myeloid leukemia.